Rubia, Hepolito E.
HRN: 25-69-32 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/23/2024
CO-AMOXICLAV 625MG (TAB)
08/23/2024
08/30/2024
PO
625mg/tab
BID
Cholecystitis
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes